<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01991873</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-KRK-0212</org_study_id>
    <secondary_id>2012-005422-30</secondary_id>
    <secondary_id>PanaMa_DE-2009-0003</secondary_id>
    <nct_id>NCT01991873</nct_id>
  </id_info>
  <brief_title>Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer</brief_title>
  <acronym>PanaMa</acronym>
  <official_title>Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, randomized, multi-center, open-label, parallel-group study to evaluate&#xD;
      the progression-free survival during maintenance therapy.&#xD;
&#xD;
      Eligible patients will be treated within a 12-week induction therapy. Those patients&#xD;
      achieving CR/PR or SD at 12 weeks and qualifying for maintenance treatment and re-induction&#xD;
      treatment with all potential drug components, will be randomized in a ratio of 1:1 to receive&#xD;
      chemotherapy plus panitumumab or chemotherapy alone during maintenance. In case of&#xD;
      progression, re-induction treatment will be started.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Until end of follow-up (24 months after randomization)</time_frame>
    <description>Progression-free survival during maintenance therapy defined as time from randomization until disease progression or death, whatever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>failure of treatment strategy</measure>
    <time_frame>Until end of follow up (24 months after randomization)</time_frame>
    <description>Time from randomization until failure (death/ progression) of treatment strategy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of re-induction</measure>
    <time_frame>From start of re-induction therapy until progress or end of follow-up (24 months after randomization)</time_frame>
    <description>Progression-free survival during re-induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response after 12 weeks of induction chemotherapy</measure>
    <time_frame>12 weeks after start of induction chemotherapy</time_frame>
    <description>Objective response after 12 weeks of induction chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective best response during maintenance and re-induction</measure>
    <time_frame>Start of maintenance- until end of re-inductin therapy (expected average of 8 months)</time_frame>
    <description>Objective best response during maintenance and re-induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until end of follow-up (24 months after randomization)</time_frame>
    <description>Overall survival measured from time of randomization and from time of registration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Until end of follow-up (24 months after randomization)</time_frame>
    <description>Overall safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health and skin related Quality of life</measure>
    <time_frame>Until end of follow-up (24 months after randomization)</time_frame>
    <description>Health and skin related Quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">387</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Maintenance Chemotherapy + Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance therapy:&#xD;
Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15&#xD;
Re-induction upon progression:&#xD;
Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.&#xD;
mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Chemotherapy w/o Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance therapy:&#xD;
Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15&#xD;
Re-induction upon progression:&#xD;
Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.&#xD;
mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance Chemotherapy</intervention_name>
    <arm_group_label>Maintenance Chemotherapy + Panitumumab</arm_group_label>
    <arm_group_label>Maintenance Chemotherapy w/o Panitumumab</arm_group_label>
    <other_name>Folinic acid + 5-FU (5-Fluorouracil)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab (Within maintenance phase)</intervention_name>
    <arm_group_label>Maintenance Chemotherapy + Panitumumab</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6 (Within re-induction phase)</intervention_name>
    <arm_group_label>Maintenance Chemotherapy + Panitumumab</arm_group_label>
    <arm_group_label>Maintenance Chemotherapy w/o Panitumumab</arm_group_label>
    <other_name>Oxaliplatin + Folinic acid + 5-FU (5-Fluorouracil)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab (Within re-induction phase)</intervention_name>
    <arm_group_label>Maintenance Chemotherapy + Panitumumab</arm_group_label>
    <arm_group_label>Maintenance Chemotherapy w/o Panitumumab</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Male or female ≥ 18 years of age&#xD;
&#xD;
          -  Histologically proven metastatic colorectal cancer&#xD;
&#xD;
          -  Molecular testing showing RAS wild-type in colorectal carcinoma cells&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST 1.1&#xD;
&#xD;
          -  Adequate bone marrow, liver, kidney, organ and metabolic function&#xD;
&#xD;
          -  Bone marrow function:&#xD;
&#xD;
               -  leukocyte count ≥ 3.0 × 109/L&#xD;
&#xD;
               -  ANC ≥ 1.5 × 109/L&#xD;
&#xD;
               -  platelet count ≥ 100 × 109/L&#xD;
&#xD;
               -  hemoglobin ≥ 9 g/dL or 5.59 mmol/L (may be transfused or treated with&#xD;
                  erythropoietin to maintain/ exceed this level)&#xD;
&#xD;
          -  Hepatic function:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × UNL&#xD;
&#xD;
               -  ALT and AST ≤ 2.5 × UNL (or ≤ 5 × UNL in presence of liver metastases)&#xD;
&#xD;
               -  AP ≤ 5 × UNL&#xD;
&#xD;
          -  Renal function:&#xD;
&#xD;
               -  Creatinine clearance ≥ 50 mL/min according to Cockcroft-Gault formula or serum&#xD;
                  creatinine ≤ 1.5 × UNL&#xD;
&#xD;
          -  Metabolic function:&#xD;
&#xD;
               -  Magnesium ≥ lower limit of normal&#xD;
&#xD;
               -  Calcium ≥ lower limit of normal&#xD;
&#xD;
          -  ECOG performance status 0 - 1&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment for colorectal cancer in the metastatic setting&#xD;
&#xD;
          -  Previous EGFR-targeting therapy &lt; 6 months after end of adjuvant therapy&#xD;
&#xD;
          -  Known brain metastases unless adequately treated (surgery or radiotherapy) with no&#xD;
             evidence of progression and neurologically stable off anticonvulsants and steroids&#xD;
&#xD;
          -  Chronic inflammatory bowel disease&#xD;
&#xD;
          -  Peripheral neuropathy ≥ NCI-CTCAE V 4.03 grade 2&#xD;
&#xD;
          -  Other previous malignancies with the exception of a history of previous curatively&#xD;
             treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix or&#xD;
             other curatively treated malignant disease without recurrence after at least 5 years&#xD;
             of follow-up&#xD;
&#xD;
          -  Significant disease that, in the investigator's opinion, would exclude the patient&#xD;
             from the study&#xD;
&#xD;
          -  History of cardiac disease; defined as:&#xD;
&#xD;
               -  Congestive heart failure &gt; New York Heart Association (NYHA) class 2&#xD;
&#xD;
               -  Active coronary artery disease (myocardial infarction more than 6 months prior to&#xD;
                  start of study treatment is allowed)&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin&#xD;
                  are permitted)&#xD;
&#xD;
               -  Uncontrolled hypertension (defined as blood pressure ≥ 160 mmHg systolic and/or ≥&#xD;
                  90 mmHg diastolic on medication)&#xD;
&#xD;
          -  Patients with interstitial lung disease, e.g., pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan&#xD;
&#xD;
          -  Known HIV, hepatitis B or C infection&#xD;
&#xD;
          -  Known hypersensitivity reaction to any of the study components&#xD;
&#xD;
          -  Radiotherapy, major surgery or any investigational drug 30 days before registration&#xD;
&#xD;
          -  Pregnancy or lactation or planning to be pregnant during treatment and within 6 months&#xD;
             after the end of treatment&#xD;
&#xD;
          -  Subject (male or female) is not willing to use highly effective methods of&#xD;
             contraception (per institutional standard) during treatment and for at least an&#xD;
             additional 6 months after the end of treatment&#xD;
&#xD;
          -  Known alcohol or drug abuse&#xD;
&#xD;
          -  Any condition that is unstable or could jeopardize the safety of the patient and his&#xD;
             compliance in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja Trarbach, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zentrum für Tumorbiologie und Integrative Medizin, Klinikum Wilhelmshaven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St.-Antonius-Hospital Eschweiler</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Tumorbiologie und Integrative Medizin, Klinikum Wilhelmshaven</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>Homepage of the AIO (Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft e.V.)</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>maintenance therapy</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>Vectibix®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

